Clinical Trial Update: Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neoplasm; currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• Elzonris (tagraxofusp)
• Venclexta (venetoclax)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Status: NOT_YET_RECRUITING